Arrowhead Pharma (ARWR) 5.78 $ARWR Arrowhead

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arrowhead Pharma (ARWR) 5.78 $ARWR

Arrowhead Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
BusinessWire - Wed Jul 06, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that president and chief executive officer Christopher Anzalone, Ph.D., will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13, 2016 at 10:45 a.m. EDT in New York.
ARWR: 5.78 (+0.05)

Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma
PR Newswire - Thu Jun 30, 7:45AM CDT
Lagging the market yesterday was the Biotech space, which continues to be challenged by costs, economic uncertainty, and policies. Stock-Callers.com reviews the recent performances of the following equities today: ImmunoGen Inc. (NASDAQ: IMGN), Immunomedics Inc. (NASDAQ: IMMU), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). Sign up for your complimentary trade alerts on these stocks at:
IMMU: 2.34 (-0.14), ARWR: 5.78 (+0.05), VNDA: 11.54 (+0.07), IMGN: 3.12 (-0.08)

Arrowhead Pharmaceuticals Initiates Phase 1/2 Single and Multiple Dose Study of Hepatitis B Candidate ARC-521
BusinessWire - Thu Jun 09, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 1/2 study of ARC-521, the company's second RNAi-based investigational medicine for the treatment of chronic hepatitis B virus (HBV) infection. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single doses of ARC-521 in healthy volunteers and the safety, tolerability, and antiviral activity of single and multiple doses of ARC-521 in patients with chronic HBV. This study may have multiple readouts, including single dose safety data, single dose antiviral activity data, and multiple dose safety and antiviral activity data.
ARWR: 5.78 (+0.05)

Arrowhead Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Fri Jun 03, 6:30AM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that chief operating officer and head of R&D Bruce Given, M.D., will present at the Jefferies 2016 Healthcare Conference on June 10, 2016 at 10:30 a.m. EDT. Investors may access live and archived versions of the audio webcast of this presentation on the Events and Presentations page under the Investors section of the Arrowhead website.
ARWR: 5.78 (+0.05)

How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.52 (+0.07), RDUS: 42.77 (+1.52), ARWR: 5.78 (+0.05), FPRX: 45.29 (+0.75)

Arrowhead Research Shares Up 20.5% Since SmarTrend's Buy Recommendation (ARWR)
Comtex SmarTrend(R) - Mon May 16, 1:43PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 3 months, Arrowhead Research has returned 20.51% as of today's recent price of $5.17.
ARWR: 5.78 (+0.05)

Arrowhead Reports Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 10, 3:01PM CDT
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
ARWR: 5.78 (+0.05)

Uptrend Call Working As Arrowhead Research Stock Rises 33.8% (ARWR)
Comtex SmarTrend(R) - Mon May 09, 1:38PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 33.80% as of today's recent price of $5.74.
ARWR: 5.78 (+0.05)

Arrowhead Pharmaceuticals' Preclinical Candidate ARC-LPA Achieves 98% Knockdown and Long Duration of Effect after Subcutaneous Administration
BusinessWire - Fri May 06, 11:00AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting lipoprotein (a), or Lp(a), for the treatment of cardiovascular disease at the Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions in Nashville. ARC-LPA is the first RNAi therapeutic program to use Arrowhead's new delivery vehicles designed for subcutaneous (SQ) administration.
ARWR: 5.78 (+0.05)

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results
BusinessWire - Tue May 03, 3:01PM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, May 10, 2016, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2016 second quarter ended March 31, 2016. Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 5054757.
ARWR: 5.78 (+0.05)

34.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Fri Apr 29, 1:18PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 34.27% as of today's recent price of $5.76.
ARWR: 5.78 (+0.05)

Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
BusinessWire - Fri Apr 29, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.
ARWR: 5.78 (+0.05)

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521
BusinessWire - Thu Apr 28, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection. Pending approval, Arrowhead intends to proceed with ARC521-1001, a first-in-human study to assess single and multiple-doses of ARC-521 in healthy volunteers and HBV patients.
ARWR: 5.78 (+0.05)

Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 5:01PM CDT
SOURCE: ARROWHEAD PHARMA Arrowhead Pharmaceuticals recently offered up insight into potential efficacy for its clinical-stage hepatitis B drug ARC-520 that suggest it may offer the best chance yet at a functional cure for hepatitis B, a common...
GILD: 87.10 (+0.55), ARWR: 5.78 (+0.05), BMY: 75.37 (+0.09)

Arrowhead Research Has Returned 42.9% Since SmarTrend Recommendation (ARWR)
Comtex SmarTrend(R) - Fri Apr 22, 12:23AM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 2 months, Arrowhead Research has returned 42.89% as of today's recent price of $6.13.
ARWR: 5.78 (+0.05)

Arrowhead Research Up 39.4% Since SmarTrend Uptrend Call (ARWR)
Comtex SmarTrend(R) - Thu Apr 14, 12:53PM CDT
SmarTrend identified an Uptrend for Arrowhead Research (NASDAQ:ARWR) on March 2nd, 2016 at $4.29. In approximately 1 month, Arrowhead Research has returned 39.39% as of today's recent price of $5.98.
ARWR: 5.78 (+0.05)

4 Hot Trending Small Cap Stocks That You Haven't Heard About
ACCESSWIRE - Thu Apr 14, 8:57AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SPWH, CONN, PEG and ARWR are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
ARWR: 5.78 (+0.05), PEG: 45.90 (-0.24), CONN: 7.20 (-0.05), SPWH: 9.68 (+0.14)

Better Buy: Inovio Pharmaceuticals or Arrowhead Research Corp.?
Keith Speights, The Motley Fool - Motley Fool - Thu Apr 14, 8:21AM CDT
Image source: Inovio Pharmaceuticals. Biotech investors have been a sad bunch lately. Politicians slamming high drug prices combined with general market uncertainties have clobbered many biotech stocks over the last several months. Arrowhead...
INO: 9.20 (+0.09), GILD: 87.10 (+0.55), ARWR: 5.78 (+0.05)

What Caused Arrowhead Pharmaceuticals to Skyrocket 13% Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 13, 3:58PM CDT
Image source: Arrowhead Pharmaceuticals. What:  After reporting data from an early-stage study of its ARC-520 in hepatitis B patients, shares of  Arrowhead Pharmaceuticals   shot 12.9% higher today. So what: The clinical-stage researcher of...
ARWR: 5.78 (+0.05), BMY: 75.37 (+0.09)

Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver Congress(TM) 2016
BusinessWire - Wed Apr 13, 6:30AM CDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that three presentations are being made on ARC-520, its investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress(TM) 2016 (ILC 2016), in Barcelona, Spain, April 13-17, 2016.
ARWR: 5.78 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 404

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

CorMedix Achieves 52-Week High Amidst Business Expansion Strategies

Updated Category News Views 122

CorMedix Stock Reaches New Heights CorMedix Inc. has recently celebrated a milestone by reaching a new 52-week high, with shares hitting $10.15. This significant achievement comes as part of a broader trend of notable expansion and investor confidence in the pharmaceutical and medical device sector. Over the past year, CorMedix's stock has increased by an impressive...

Continue Reading
Norway's Wealth Fund Shifts Ethics Standards Amid Gaza Conflict

Updated Category News Views 148

Norway's Wealth Fund Takes a Stand on Ethical Investments Norway's $1.7 trillion wealth fund is currently navigating a challenging ethical landscape as it considers pulling investments from companies associated with operations in the occupied Palestinian territories. The fund's Council on Ethics has adopted a stricter interpretation of its ethical standards, which could...

Continue Reading
Bonduelle's Monthly Share and Voting Rights Update

Updated Category News Views 120

Overview of Bonduelle's Monthly Share and Voting Rights Update Bonduelle, a prominent player in the food industry, is well-known for its commitment to providing high-quality vegetable products. Headquartered in an innovative facility, their corporate structure includes a significant capital invested which showcases their strong market presence. Latest Information on...

Continue Reading
Innovative Partnership Launches Unique Aging and Cancer Research Institute

Updated Category News Views 193

Innovative Partnership in Cancer Research The Mark Foundation for Cancer Research (MFCR) and the Samuel Waxman Cancer Research Foundation (SWCRF) have entered a groundbreaking collaboration to create the Samuel Waxman Institute for Aging & Cancer. This institute will serve as the first dedicated global center exploring how aging impacts cancer risk throughout a person's...

Continue Reading
Market Overview: Nasdaq Surges as Stocks Show Mixed Trends

Updated Category News Views 201

Market Overview: Nasdaq Shows Strength The U.S. stock markets experienced a mixed performance recently, with the Nasdaq Composite recording a notable gain of over 50 points. This uptick brings attention to sector volatility and specific stock behaviors that investors should closely monitor. Daily Market Trends After the markets opened, the Dow Jones Industrial Average saw...

Continue Reading